Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mucosal vaccine composition

一种疫苗组合物、粘膜的技术，应用在药物组合、微生物、药物输送等方向，能够解决不明确、难以防御感染自身等问题

Inactive Publication Date: 2016-04-27
NITTO DENKO CORP
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Injectable vaccines have the problem of inducing an immune response (IgG antibody production) in the blood (systemic) without inducing an immune response (IgA antibody production) in the mucous membranes, although it can prevent the pathogens caused by infection. proliferates, but has difficulty defending itself from infection by pathogens due to the mucosal route
Thus, from the example of the vaccine using lipopolysaccharide (LPS) derived from Pantoea agglomerans (Pantoea agglomerans) described in this patent document 3, the oral mucosa, eye mucosa, ear mucosa, genital mucosa, throat mucosa, respiratory tract mucosa , bronchial mucosa, pulmonary mucosa, gastric mucosa, intestinal mucosa, or rectal mucosa, it is unclear whether lipopolysaccharide (LPS) derived from Pantoea agglomerans (Pantoea agglomerans) exerts an effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mucosal vaccine composition
  • Mucosal vaccine composition
  • Mucosal vaccine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0117] 2.25 μL (445 μg / mL) of a solution containing influenza vaccine antigen (B / Wisconsin / 1 / 2010, manufactured by Osaka University Institute of Microbial Diseases) and lipopolysaccharide derived from Pantoea agglomerans (NACALAITESQUE, INC. Phosphate buffer (manufactured by NACALAITESQUE, INC.) was added to 5 μL (2 mg / mL) of the solution to prepare 300 μL of a mucosal vaccine composition.

[0118] Six mice (8-week-old female BALB / C mice, Japan SLC, Inc.) were anesthetized, and 30 μL of the prepared vaccine composition was sublingually administered to each mouse. One week after the administration, the mice were anesthetized again, and 30 μL of the prepared vaccine composition was sublingually administered to each mouse. After the second administration and one week later, the serum and nasal cavity washing fluid of the mice were collected, and for the titer of influenza HA (type B)-specific IgG in the serum and the specific IgA of influenza HA (type B) in the nasal cavity washing...

Embodiment 2

[0124] Add 1.25 μL (801 μg / mL) of a solution containing influenza vaccine antigen (A / California / 07 / 2009 (H1N1), manufactured by Osaka University Institute of Microbial Diseases) and lipopolysaccharide (NACALAITESQUE , INC.) was added to 5 μL (2 mg / mL) of a phosphate buffer solution (NACALAITESQUE, INC.) to prepare a 300 μL mucosal vaccine composition.

[0125] Six mice (8-week-old female BALB / C mice, Japan SLC, Inc.) were anesthetized, and 30 μL of the prepared mucosal vaccine composition was sublingually administered to each mouse. One week after the administration, the mice were anesthetized again, and 30 μL of the prepared mucosal vaccine composition was sublingually administered to each mouse. After the second administration and one week later, the serum and nasal cavity washing fluid of the mice were collected, and the influenza HA (H1N1) specific IgG titer in the serum and the influenza HA (H1N1) specific IgA titer in the nasal cavity washing fluid were collected. The d...

reference example 1

[0131] A sample containing the same antigen and immunostimulant as in the sample administered in Example 1, and the same (antigen / immunostimulant) as in Example 1 was produced, and its safety was evaluated. That is, 225 μL (445 μg / mL) of a solution containing influenza vaccine antigen (B / Wisconsin / 1 / 2010, manufactured by Osaka University Institute of Microbial Diseases) and lipopolysaccharide derived from Pantoea agglomerans (NACALAITESQUE, INC .) solution (2 mg / mL) was added to 500 μL (2 mg / mL) of phosphate buffer (NACALAITESQUE, INC.) to prepare 1000 μL of vaccine composition.

[0132] Eight mice (8-week-old female BALB / C mice, Japan SLC, Inc.) were anesthetized, and 100 μL of the prepared vaccine composition was subcutaneously administered to each mouse. The mice were followed up to 72 hours after the administration, and the survival rate was observed.

[0133] (Refer to Comparative Examples 1 and 2)

[0134] Instead of the lipopolysaccharide derived from Pantoea agglomer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The purpose of the present invention is to provide a mucosal vaccine composition that is effective and safe as a prophylactic or therapeutic drug for infections and cancer, which effectively induces a systemic immune response and mucosal immune response, and which can be administered to the oral mucosa, ocular mucosa, ear mucosa, genital mucosa, pharyngeal mucosa, respiratory mucosa, bronchial mucosa, pulmonary mucosa, gastric mucosa, intestinal mucosa, or rectal mucosa. The present invention is a mucosal vaccine composition administered to at least one mucous membrane of a person or animal, said mucous membrane being selected from the group consisting of oral mucosa, ocular mucosa, ear mucosa, genital mucosa, pharyngeal mucosa, respiratory mucosa, bronchial mucosa, pulmonary mucosa, gastric mucosa, intestinal mucosa, and rectal mucosa. The mucosal vaccine composition is characterized by including at least one type of antigen, and, as an immunostimulant, a lipopolysaccharide or a salt thereof derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter.

Description

technical field [0001] The present invention relates to an agent useful as a preventive or therapeutic agent for infectious diseases and cancer, and capable of treating oral mucosa, ocular mucosa, ear mucosa, genital mucosa, throat mucosa, respiratory tract mucosa, bronchial mucosa, lung mucosa, gastric mucosa, intestinal mucosa or Mucosal vaccine compositions for rectal mucosal administration. In particular, the present invention relates to a mucosal vaccine composition capable of safely and effectively inducing a systemic immune response and a mucosal immune response by administering a specific lipopolysaccharide as an adjuvant to the mucosal surface together with an antigen. Background technique [0002] As the dosage form of vaccine preparations, most of the commercialized preparations are now injections. Injectable vaccines have the problem of inducing an immune response (IgG antibody production) in the blood (systemic) without inducing an immune response (IgA antibody...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K9/06A61K9/08A61K9/12A61K9/20A61P31/04A61P31/12A61P31/16A61P37/04A61K39/145
CPCA61K9/006A61K39/04A61K39/08A61K39/12A61K39/385A61K2039/541A61K2039/55572A61K2039/575A61P31/00A61P31/04A61P31/12A61P31/16A61P35/00A61P37/04C12N2710/16734C12N2710/20034C12N2720/12334C12N2730/10134C12N2760/16034C12N2760/16134C12N2760/16234C12N2760/18434C12N2760/18734C12N2760/20134C12N2770/24134C12N2770/32434C12N2770/32634C12N2770/36234A61K39/092A61K39/13A61K39/145A61K39/15A61K39/155A61K39/165A61K39/20A61K39/205A61K39/25A61K39/29A61K39/292C12N7/00
Inventor 深坂昌弘堀光彦大久保胜之浅利大介冈崎有道清远英司松下恭平
Owner NITTO DENKO CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com